Platinum-Gold Compounds as Potential Chemo- and Targeted Agents for Ovarian Cancer
Funded at Brooklyn College · NIH-11353862 · Data updated 2026-11-12
A new platinum(IV)-gold compound approach could offer a more effective and targeted treatment for ovarian cancer patients, potentially reducing resistance and side effects of current platinum therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brooklyn College NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 4, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $157,150 |
| NIH project number | 5R16GM149396-04 |
| Project ID | NIH-11353862 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are women with ovarian cancer who may benefit from novel platinum(IV)-gold therapies and who can participate in early-phase preclinical-to-clinical translation efforts.
✕Less likely to help
Patients whose cancer does not respond to metal-based therapies or who are not suitable for this specific investigational approach may not benefit.
What this research studies
This project explores platinum(IV)-gold anticancer agents designed to work inside ovarian cancer cells, aiming to release potent platinum and gold drugs that attack multiple targets. By developing compounds with improved pharmacology, the research hopes to overcome resistance seen with standard platinum therapies. The work involves chemical design, synthesis, and preclinical testing to assess how these agents behave in ovarian cancer models and their potential to trigger immune responses against tumors. If successful, the approach could lead to new treatments that are more effective and selective for ovarian cancer patients.
Why it matters
Potential benefit: If successful, patients with ovarian cancer could have a new treatment option that overcomes resistance and reduces side effects compared to current platinum therapies.
How similar studies have gone: Previous metal-based anticancer strategies have shown promise in preclinical settings, but this exact Pt(IV)-Au approach is exploratory and not yet proven in patients.
Where this research is happening
-
Brooklyn College
New York, United States Active
Researchers
- Principal investigator: Contel, Maria — Brooklyn College
- Study coordinator: Contel, Maria
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.